Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2000-04-17
2008-12-30
Le, Emily M. (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S235100, C435S456000
Reexamination Certificate
active
07470426
ABSTRACT:
The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.
REFERENCES:
patent: 5124148 (1992-06-01), Csatary et al.
patent: 5198336 (1993-03-01), Knobeloch et al.
patent: 5215745 (1993-06-01), Csatary et al.
patent: 5273745 (1993-12-01), Schirrmacher
patent: 5274137 (1993-12-01), Nicolaou et al.
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5602023 (1997-02-01), Csatary
patent: 5633274 (1997-05-01), Halperin et al.
patent: 5677178 (1997-10-01), McCormick
patent: 5688773 (1997-11-01), Chiocca et al.
patent: 5698443 (1997-12-01), Henderson et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 39 22 444 (1991-10-01), None
patent: 0 292 293 (1988-11-01), None
patent: 0 292 293 (1988-11-01), None
patent: 0 514 603 (1992-11-01), None
patent: 0 564 121 (1993-10-01), None
patent: 0 583 142 (1994-02-01), None
patent: 1 314 431 (2003-05-01), None
patent: 1069144 (1967-05-01), None
patent: A 58-116422 (1983-07-01), None
patent: WO 86/00529 (1986-01-01), None
patent: WO 86/00811 (1986-02-01), None
patent: WO 89/07445 (1989-08-01), None
patent: WO 93/18790 (1993-09-01), None
patent: WO 94/16716 (1994-08-01), None
patent: 94/19022 (1994-09-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 94/25627 (1994-11-01), None
patent: WO 95/32706 (1995-12-01), None
patent: WO 96/00007 (1996-01-01), None
patent: WO 96/03997 (1996-02-01), None
patent: 96/26285 (1996-08-01), None
patent: 96/34625 (1996-11-01), None
patent: WO 97/01358 (1997-01-01), None
patent: WO 97/04805 (1997-02-01), None
patent: WO 97/26904 (1997-07-01), None
patent: WO 99/04026 (1999-01-01), None
patent: WO 99/08692 (1999-02-01), None
patent: 99/18799 (1999-04-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 99/29343 (1999-06-01), None
patent: 99/45783 (1999-09-01), None
patent: WO 99/55345 (1999-11-01), None
patent: WO 99/64068 (1999-12-01), None
patent: WO 00/45853 (2000-08-01), None
patent: WO 00/54795 (2000-09-01), None
patent: 00/62735 (2000-10-01), None
Lorence et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 86 (16): 1228-33, 1994.
National Cancer Institute. Newcastle Disease virus (PDQ®): Complementary and Alternative Medicine, 47 pages.
Kirn et al. Replicating viruses as selective cancer therapeutics, Molecular Medicine Today, 1996, vol. 2, 519-527.
Eck et al. Gene-Based Therapy. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9thEdition, chapter 5.
Verma et al. Gene Therapy—Promises, Problems, and Prospects. Nature, vol. 389, pp. 239-242.
Lorence, R.M., et al,Cancer Research, 54: 6017-6021, Dec. 1, 1994 “Complete Regression of Human Fibrosarcomaj Xenografts after Local Newcastle Disease Virus Therapy”.
Database Caplus, on STN Columbus (OH):chemical abstract service, DN 116: 104333, CN 1054192 A. Zheng, B., “Attenuated new castle disease virus for induction of interferons to combat neoplasm or viral diseases,” Abstract, Apr. 9, 1991.
Gresser, et al, “Exogenous Interferon and Inducers of Interferon in the Treatment of Balb/c Mice Inoculated with RC19 Tumor Cells,”Nature, Aug. 23, 1969, vol. 223, pp. 844-845.
Csatary, L.K., et al, Orvosi Hetilap 131: 2585-2588, 1990, “Virus Vaccines For The Tratment of Cancer”.
Kirchner, H.H., et al, World J Urol. (1995) 13:171-173, “Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines”.
Murphy, Frederick A., et al, Virology, Second Edition, 1990, Chapter 2, pp. 9-35, “Virus Taxonomy”.
Csatary, Laszlo K., The Lancet, Oct. 9, 1971, p. 825, “Viruses in the Treatment of Cancer”.
Ahlert, T., et al, Cancer Res. 50 (1990), pp. 5962-5968, “Isolation of a Human Melanoma Adapted Newcastle Disease Virus Mutant with Highly Selective Replication Patterns”.
Hashiro, G., et al,Archives of Virology54, 307-315 (1977) “The Preferential Cytotoxicity of Reovirus for Certain Transformed Cell Lines”.
Blaese, R.M., et al, European Journal of Cancer, vol. 30A, No. 8, pp. 1190-1193, 1994, “In situ Delivery of Suicide Genes for Cancer Treatment”.
Zhang, Jian Feng, et al, Cancer Gene Therapy, vol. 3, No. 1, 1996, pp. 31-38, “Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression”.
Peplinski, Gary R., et al, Annals of Surgical Oncology, 3(2):15-23, “Prevention of Murine Breast Cancer by Vaccination with Tumor Cells Modified by Cytoline-Producing Recombinant Vaccinia Viruses”.
Cotran, Ramzi S., M.D., et al, Robbins Pathologic Basis of Disease, 4th Edition, p. 251, “Kinetics of Tumor Cell Growth”.
Schloer, G.M., et al, Journal of Virology, vol. 2, No. 1, Jan. 1968, pp. 40-47, “Relationship of Plaque Size and Virulence for Chickens of 14 Representative Newcastle Disease Virus Strains”.
Tait, David L., et al, Clinical Cancer Research, vol. 3, pp. 1959-1968, Nov. 1997, “A Phase I Trial of Retroviral BRCA1sv Gene Therapy in Ovarian Cancer”.
Martuza, Robert L., et al, Science, vol. 252, pp. 854-855, May 10, 1991, “Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant”.
Hanson, R.P., et al, Science, vol. 122, pp. 156-157, Jul. 22, 1955, “Identification of Vaccine Strains of Newcastle Disease Virus”.
Chambers, Renee, et al, Proc. Natl. Acad. Sci. USA, vol. 92, pp. 1411-1415, Feb. 1995, “Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma”.
Asada, Teruo, MD, Cancer, vol. 34, pp. 1907-1928, Dec. 1974, “Treatment of Human Cancer with Mumps Virus”.
Sreevalsan, Thazepadath, Biologic Therapy of Cancer: Principles and Practice, pp. 347-364, Chapter 14 Biologic Therapy with Interferon-∀ and ∃: Preclinical Studies.
Stoner, Gary D., et al, Nature, vol. 245, Oct. 12, 1973, pp. 319-320, “Effect of Neuraminidase pretreatment on the Susceptibility of Normal and Transformed Mammalian Cells to Bovine Enterovirus 261”.
Joklik, W.K., Virology, Second Edition 1990, pp. 383-410, “Interferons”.
Schnell, Matthias, J., et al, Cell, vol. 90, pp. 849-857, Sep. 5, 1997, “Construction of a Novel Virus that Targets HIV-1-Infected Cells and Controls HIV-1 Infection”.
Lorence, Robert M., et al, Journal of the National Cancer Institute, vol. 86, No. 16, Aug. 17, 1994, pp. 1228-1233, Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy.
Beattie, Elizabeth, et al, Virus Genes, 12:1, 89-94, 1996, “Host-Range Restriction of Vaccinia Virus E3L-Specific Deletion Mutants”.
Howard, Brad, et al, Annals New York Academy of Sciences, Duke University Medical Center, p. 167-187, “Retrovirus-Mediated Gene Transfer of the Human (-IFN Gene: A Therapy for Cancer”.
Suskind, R.G., et al, US Dept. of Health, Education, & Welfare, N.I.H., National Institute of Allergy and Infectious Diseases, and National Cancer Inst., Bethesda, Md. Oncolytic Effect of Coxsackie Virus, pp. 309-318, “Viral Agents Oncolytic for Human Tumors in Heterologous Host. Oncolytic Effect of Coxsackie B. Viruses.” (22932), Oct. 29, 1956.
Bluming, Avrum Z., et al, The Lancet, Jul. 10, 1971, p. 105-106 “Regression of Burkitt's Lymphoma . . . Association With measles Infection”.
Pasquinucci, G., The Lancet, Jan. 16, 1971, i, 136 “Possible Effect of Measles on Leukaemia”.
Gross, Samuel, The Lancet, Feb. 20, 1971, p. 397-398, “Mea
Groene William S.
Lorence Robert M.
Rabin Harvey
Roberts Michael S.
von Borstel Reid W.
Le Emily M.
Nixon & Vanderhye
Wellstat Biologics Corporation
LandOfFree
Treatment of neoplasms with viruses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of neoplasms with viruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of neoplasms with viruses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4033944